300759: Pharmaron Beijing Co., Ltd. - Summary | Jitta

Pharmaron Beijing Co., Ltd.

CHN:300759

Price
CN¥64.76
Loss Chance
44.6%
6.86JITTA SCORE
68.67%Over Jitta Line
Jitta Ranking
203 / 456
1,846 / 4,821
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (66)
Recent Business Performance (38)
Financial Strength (79)
Return to Shareholders (59)
Competitive Advantage (72)
Jitta Signs
Revenue and EarningConsistent High Growth in the past 5 years
Recent Business PerformanceEarning Growth Last Year
Dividend PayoutIncreasing Every Year
Interest Coverage RatioVery Good
SG&A to SalesDecreasing Every Year
Recent IPOLess than 3 years
CapExVery High
Key Stats
Jitta Score
Jitta Line
6.86
68.67%
4.77
747.44%
Life Sciences Tools and Services
7.95
136.93%
6.60
60.19%
5.21
665.09%
COMPANY DESCRIPTION
Pharmaron Beijing Co., Ltd., together with its subsidiaries, provides pharmaceutical research and development services to the life sciences industry in North America, Europe, Mainland China, rest of Asia, and internationally. The company operates through five segments: Laboratory Services; Chemistry, Manufacturing and Controls (CMC) Services; Clinical Development Services; Biologics and Cell and Gene Therapy Services; and Others. It offers laboratory chemistry solutions, including medicinal, synthetic, and analytical and purification chemistry, as well as computer-aided drug design services; bioscience services comprising in vitro and in vivo drug metabolism and pharmacokinetics/absorption, distribution, metabolism, and excretion solutions; and in vitro biology and in vivo pharmacology, safety assessment, and the U.S. laboratory services. The company also provides process development and manufacturing, material science/pre-formulation, formulation development and manufacturing, and analytical development services; and radiolabelled science services and early stage clinical trial services, as well as clinical research and site management services. It also provides business development; and contract research, development, and manufacturing services for pharmaceutical products. The company was incorporated in 2004 and is headquartered in Beijing, the People's Republic of China.